《大行》摩通升科伦博泰(06990.HK)目标价至648元 公司研究取得积极成果

阿斯达克财经
Jul 17

摩根大通发表研究报告指,科伦博泰(06990.HK) 近日股价表现强劲,相信主要是由于靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT),在中国进行的OptiTROP-Lung06三期临床试验达到主要终点,是首次有ADC+PD-1联合疗法在这个阶段展示出显著优于Keytruda+化疗的疗效。此外,国家药监局已对sac-TMT用于TNBC的补充新药申请授予...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10